- Home
- SCLX vs HSPO Comparison
SCLX vs HSPO Comparison
Compare SCLX & HSPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- HSPO
- Stock Information
- Founded
- SCLX 2011
- HSPO 2014
- Country
- SCLX United States
- HSPO United States
- Employees
- SCLX N/A
- HSPO N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- HSPO Blank Checks
- Sector
- SCLX Health Care
- HSPO Finance
- Exchange
- SCLX Nasdaq
- HSPO Nasdaq
- Market Cap
- SCLX 51.3M
- HSPO 49.4M
- IPO Year
- SCLX N/A
- HSPO 2022
- Fundamental
- Price
- SCLX $4.06
- HSPO $11.90
- Analyst Decision
- SCLX Strong Buy
- HSPO
- Analyst Count
- SCLX 4
- HSPO 0
- Target Price
- SCLX $396.67
- HSPO N/A
- AVG Volume (30 Days)
- SCLX 103.2K
- HSPO 2.6K
- Earning Date
- SCLX 05-12-2025
- HSPO 01-01-0001
- Dividend Yield
- SCLX N/A
- HSPO N/A
- EPS Growth
- SCLX N/A
- HSPO N/A
- EPS
- SCLX N/A
- HSPO 0.27
- Revenue
- SCLX $56,590,000.00
- HSPO N/A
- Revenue This Year
- SCLX $115.30
- HSPO N/A
- Revenue Next Year
- SCLX $73.33
- HSPO N/A
- P/E Ratio
- SCLX N/A
- HSPO $44.77
- Revenue Growth
- SCLX 21.07
- HSPO N/A
- 52 Week Low
- SCLX $5.80
- HSPO $10.87
- 52 Week High
- SCLX $80.50
- HSPO $12.41
- Technical
- Relative Strength Index (RSI)
- SCLX 24.27
- HSPO 53.02
- Support Level
- SCLX $3.60
- HSPO $11.79
- Resistance Level
- SCLX $7.64
- HSPO $11.99
- Average True Range (ATR)
- SCLX 1.21
- HSPO 0.02
- MACD
- SCLX -0.37
- HSPO -0.01
- Stochastic Oscillator
- SCLX 6.67
- HSPO 36.92
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.